Phase II Trial of OSI-774 (Tarceva), a Human Epidermal Growth Factor (HER) (erbB, Also Known as Epidermal Growth Factor Receptor, EGFR) Tyrosine Kinase Inhibitor, in Treatment-Naïve Operable Breast Cancer.
Phase of Trial: Phase II
Latest Information Update: 04 Sep 2012
At a glance
- Drugs Erlotinib (Primary)
- Indications Breast cancer
- Focus Therapeutic Use
- 10 Jun 2017 Biomarkers information updated
- 10 Jul 2008 Status changed from in progress to completed, reported by ClinicalTrials.gov.
- 24 Jul 2007 New trial record.